Advanced mobility company Human in Motion Robotics said its XoMotion exoskeleton has earned its first regulatory approval, meaning it can be marketed and sold in Canada. The self-balancing, hands-free orthopedic device is designed to help patients with spinal cord injuries, ones who have suffered a stroke, and people dealing with other neurological conditions.
XoMotion, which is based on other advanced humanoid robotics, is intended to assist physical therapists by helping to lift, mobilize and train patients. The exoskeleton is capable of performing a wide range of ambulatory tasks.
Most Read Medical News:
- FDA Approves Glucose Monitor That Can Be Worn for a Year
- Walgreens Pays $106M to Settle Allegations it Submitted False Payment Claims for Prescriptions
- Total Artificial Heart Implanted in First Human Patient
- StatLab Begins Manufacturing its Own Slides and Coverglass
Human in Motion Robotics recently received its Medical Devices Establishment License to market and sell XoMotion in Canada, marking a significant milestone as the first step toward providing widespread global access to patients and care providers. With this approval, XoMotion became the first self-balancing exoskeleton system available for acquisition in Canada. Looking ahead, the company will focus on gaining clearance in other important global markets, including the US, Asia, and the EU.
"With XoMotion, we are setting a new standard in rehabilitation technology. Our exoskeleton not only empowers patients by facilitating natural and functional movement but also supports therapists by reducing the physical demands of their work," said Siamak Arzanpour, CEO of Human in Motion Robotics. "Gaining regulatory approval from Health Canada is a crucial step towards our goal of global accessibility, and we are committed to continuing this progress in other key markets."
XoMotion is now available for acquisition in rehabilitation and research facilities in Canada and is globally available to scientific investigators conducting rehabilitation or robotics research.
